• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Boundless Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/9/25 7:05:23 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BOLD alert in real time by email
    8-K
    false000178230300017823032025-05-092025-05-09

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 09, 2025

     

     

    Boundless Bio, Inc.

    (Exact Name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-41989

    83-0751369

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    10955 Alexandria Way, Suite 100,

     

    San Diego, California

     

    92121

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (858) 766-9912

     

    N/A

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Common Stock, par value $0.0001 per share

     

    BOLD

     

    Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 2.02 Results of Operations and Financial Condition.

    On May 9, 2025, Boundless Bio, Inc. (the Company) issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

    In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof and regardless of any general incorporation by reference language in any such filing, unless the Company specifically states in such filing that such information, or a portion thereof, is to be considered “filed” rather than furnished or incorporated by reference therein.

    Item 9.01 Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit

    Number

    Description

    99.1

    Press Release Issued on May 9, 2025

    104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    BOUNDLESS BIO, INC.

     

     

     

     

    Date:

    May 9, 2025

    By:

    /s/ Jessica Oien

     

     

     

    Name: Jessica Oien
    Title: Chief Legal Officer and Corporate Secretary

     


    Get the next $BOLD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BOLD

    DatePrice TargetRatingAnalyst
    6/2/2025$5.00Buy
    H.C. Wainwright
    5/28/2025$3.00Outperform → Market Perform
    Leerink Partners
    12/13/2024Buy → Neutral
    Guggenheim
    More analyst ratings

    $BOLD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights

    BBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment BBI-940 is on track for submission of an investigational new drug application in the first half of 2026 $127 million in cash supports operations into the first half of 2028, throughexpected proof-of-concept clinical readouts for both programs SAN DIEGO, Aug. 05, 2025 (GLOBE NEWSWIRE) --  Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced financial results and business highlights for the fisc

    8/5/25 7:00:00 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board

    HOUSTON, July 31, 2025 /PRNewswire/ -- The Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology discoveries into cures, announced today the appointment of Carolyn Ng to its external advisory board. A current business unit partner at TPG Life Sciences Innovations, Ng brings expertise in biotech and company building with a track record of guiding early to midstage companies across a wide range of therapeutic areas. "Carolyn's deep understanding of translational science, combined with her passion for fostering high-impact ventures, makes her an ideal addition to the board," said Omid Veiseh, professor of b

    7/31/25 7:00:00 AM ET
    $BCAX
    $BCYC
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

    SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that   Zachary Hornby, President and Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference. The fireside chat session is scheduled for Monday, June 9, in Miami, FL, at 9:20 a.m. ET. A live and archived webcast of the session will be accessible under "Events & Presentations" in the Investors section of Boundless Bio's website. About Boundless

    6/5/25 4:58:28 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLD
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Boundless Bio Inc.

    SCHEDULE 13G/A - Boundless Bio, Inc. (0001782303) (Subject)

    8/14/25 5:57:29 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Boundless Bio Inc.

    10-Q - Boundless Bio, Inc. (0001782303) (Filer)

    8/5/25 7:10:20 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boundless Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Boundless Bio, Inc. (0001782303) (Filer)

    8/5/25 7:05:28 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Brennan Christine

    4 - Boundless Bio, Inc. (0001782303) (Issuer)

    6/23/25 5:21:20 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Christensen James

    4 - Boundless Bio, Inc. (0001782303) (Issuer)

    6/23/25 5:16:53 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Lew Jennifer

    4 - Boundless Bio, Inc. (0001782303) (Issuer)

    6/23/25 5:15:17 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Boundless Bio with a new price target

    H.C. Wainwright initiated coverage of Boundless Bio with a rating of Buy and set a new price target of $5.00

    6/2/25 8:50:41 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boundless Bio downgraded by Leerink Partners with a new price target

    Leerink Partners downgraded Boundless Bio from Outperform to Market Perform and set a new price target of $3.00

    5/28/25 8:09:07 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boundless Bio downgraded by Guggenheim

    Guggenheim downgraded Boundless Bio from Buy to Neutral

    12/13/24 7:26:11 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLD
    Leadership Updates

    Live Leadership Updates

    View All

    Rice Biotech Launch Pad welcomes Carolyn Ng to external advisory board

    HOUSTON, July 31, 2025 /PRNewswire/ -- The Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of Rice University's health and medical technology discoveries into cures, announced today the appointment of Carolyn Ng to its external advisory board. A current business unit partner at TPG Life Sciences Innovations, Ng brings expertise in biotech and company building with a track record of guiding early to midstage companies across a wide range of therapeutic areas. "Carolyn's deep understanding of translational science, combined with her passion for fostering high-impact ventures, makes her an ideal addition to the board," said Omid Veiseh, professor of b

    7/31/25 7:00:00 AM ET
    $BCAX
    $BCYC
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

    SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced that Robert ("Bob") Doebele, M.D., Ph.D., has been appointed as Chief Medical Officer. "We are excited to have Bob join Boundless at this pivotal time as we continue to advance the BBI-355 Phase 1/2 POTENTIATE trial and approach the selection of a development candidate for our Kinesin program," said Zachary Hornby, President and Chief Executive Officer of Boundless Bio. "Bob has been a driving force behind precisio

    2/3/25 10:00:00 AM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLD
    Financials

    Live finance-specific insights

    View All

    Boundless Bio Announces Portfolio Prioritization and Runway Extension

    Portfolio prioritization focuses on novel-novel combination therapy of BBI-355 and BBI-825 and new development candidate, BBI-940, for novel kinesin program Operating runway extended into the first half of 2028, through expected proof-of-concept clinical readouts for each program Conference call and webcast to be held Tuesday, May 27 at 8:00 am ET SAN DIEGO, May 23, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (NASDAQ:BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today provided business updates focused on optimizing the Company's portfolio for p

    5/23/25 4:01:00 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BOLD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Boundless Bio Inc.

    SC 13D - Boundless Bio, Inc. (0001782303) (Subject)

    10/29/24 6:32:08 PM ET
    $BOLD
    Biotechnology: Pharmaceutical Preparations
    Health Care